Work

Paclitaxel/PT-S264 co-loaded PLGA nanofiber membranes for localized ovarian cancer peritoneal therapy with tumor-associated macrophage lipid–mitochondrial remodeling

Year: 2026
Type: article
Abstract: Introduction Ovarian cancer frequently disseminates within the peritoneal cavity, where tumor deposits, ascites, adipocyte-rich stromal tissue, and immune cells form a local microenvironment that supports tumor persistence and therapeutic resistance. Localized peritoneal drug delivery may increase regional drug exposure, but conventional intraperitoneal chemotherapy does not provide sustained spatial release at tumor-bearing surfaces and does not directly address the immunometabolic state of tumor-associated macrophages. This study developed a paclitaxel/PT-S264 co-loaded poly (lactic-co-glycolic acid) nanofiber membrane for localized ovarian cancer peritoneal therapy and evaluated its release kinetics, macrophage immunometabolic effects, ovarian cancer cell responses, and antitumor activity in an immunocompetent peritoneal model. Methods PLGA nanofiber membranes were prepared by electrospinning and tested as blank, paclitaxel-loaded, or paclitaxel/PT-S264 co-loaded formulations. Formulation quality control, in vitro release testing, tumor-conditioned macrophage assays, ovarian cancer cell functional assays, and in vivo validation were performed in a predefined workflow. The primary mechanistic endpoint was a tumor-associated macrophage lipid–mitochondrial immunosuppression score integrating lipid droplet area, lipid droplet–mitochondrial coupling, fatty-acid-oxidation-linked oxygen consumption, CD206-positive macrophages, and CD86-positive macrophages. Results Membrane batch testing showed bead-free fibers, residual hexafluoroisopropanol below 50 ppm, 24-h paclitaxel burst release below 25%, day-14 paclitaxel release of 73% in the co-loaded formulation, and day-14 PT-S264 release of 68%. Compared with paclitaxel-loaded membrane eluate, paclitaxel/PT-S264 co-loaded membrane eluate further reduced lipid droplet area from 100.5 ± 4.2 to 69.5 ± 6.1 arbitrary units per macrophage, lipid droplet–mitochondrial Pearson correlation coefficient from 0.457 ± 0.028 to 0.293 ± 0.045, and fatty-acid-oxidation-linked oxygen consumption from 51.0 ± 9.3 to 33.3 ± 3.4 arbitrary units. The co-loaded membrane also reduced CD206-positive macrophages from 46.1 ± 2.0% to 27.4 ± 1.6%, increased CD86-positive macrophages from 24.0 ± 2.6% to 40.0 ± 3.1%, and decreased the integrated immunosuppression score from 0.135 ± 0.071 to −0.461 ± 0.034. In ovarian cancer cell assays, co-loaded membrane eluate reduced direct ID8-luc viability to 45.2 ± 5.8%, spheroid area to 43.5 ± 8.6% of control, and invasion index to 44.0 ± 8.7% of control. In vivo , the co-loaded membrane reduced day-28 abdominal bioluminescence tumor burden from 4.71 ± 0.72 × 10 7 photons/s in the paclitaxel-loaded membrane group to 2.43 ± 0.75 × 10 7 photons/s, with parallel reductions in ascites volume, peritoneal nodule count, and visible tumor weight. Endpoint immune profiling showed fewer F4/80-positive CD206-positive tumor-associated macrophages, more F4/80-positive CD86-positive macrophages, and a higher CD8/Treg ratio after co-loaded membrane treatment. In a free-drug matrix, 30 nM paclitaxel and 3 µM PT-S264 produced single-agent inhibition of 25.0 ± 1.0% and 28.0 ± 1.0%, respectively; combination inhibition was 61.0 ± 2.1%, compared with a Bliss expectation of 46.0 ± 1.5%, corresponding to a Bliss excess of 15.0 ± 0.6 percentage points and an HSA excess of 33.0 percentage points; the interaction was therefore classified as synergistic under the tested conditions. Discussion These findings support a focused local-treatment strategy in which a PLGA nanofiber membrane provides sustained paclitaxel delivery together with macrophage lipid–mitochondrial immunometabolic remodeling observed in the PT-S264-containing co-loaded formulation. Although the separate free-drug concentration matrix demonstrated a synergistic interaction between paclitaxel and PT-S264 under the tested 72-h exposure conditions, as classified by the Bliss independence and HSA reference models, the membrane-formulation study did not include a PT-S264-only membrane or a factorial membrane-formulation dose-response design; therefore, the independent contribution of membrane-delivered PT-S264 and the nature of the interaction within the co-loaded membrane were not determined. Further pharmacokinetic, biodistribution, mechanistic rescue, membrane-formulation dose-response, long-term safety, and model-diversity studies are required before clinical translation.
Language: English
Subfield: Biomaterials
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236656758
FWCI:
Cites: 25
Cited by:
Related to: 10